Can I Take Reishi Mushroom with Nurtec ODT (Rimegepant)?

Import from "@/components/mdx"

What Is Rimegepant and Why Do So Many Women Take It?

Rimegepant (Nurtec ODT) is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA for acute migraine treatment and for episodic migraine prevention. Migraine is roughly three times more common in women than men, and hormonal fluctuation is one of the most frequently reported triggers.

The menstrual cycle connection is real. Estrogen withdrawal in the late luteal phase drops CGRP signaling thresholds, making migraines more likely in the two days before and the first three days of menstruation. A 2021 analysis in Cephalalgia confirmed that perimenstrual migraine attacks are longer, more severe, and less responsive to triptans than attacks at other cycle phases. Rimegepant's dual acute-plus-prevention label makes it one of the first options that can address both the unpredictable acute attack and the predictable hormonal pattern.

How rimegepant is metabolized

Rimegepant is primarily metabolized by CYP3A4 and, to a lesser extent, CYP2C9. Its half-life is approximately 11 hours. Because CYP3A4 handles most of its clearance, anything that inhibits or induces this enzyme can meaningfully change how much rimegepant stays in your body and for how long.

The FDA label states that strong CYP3A4 inhibitors are contraindicated with rimegepant because they can more than double rimegepant plasma exposure (AUC). Moderate CYP3A4 inhibitors require a dose adjustment: take rimegepant no more than once every 48 hours rather than once every 24 hours.

Life-stage context

• Reproductive years. If you track your cycle and notice your migraines cluster perimenstrually, rimegepant taken every other day starting two days before your expected period may reduce attack frequency. The BHF-301 trial (NCT03732638) showed a statistically significant reduction in migraine days with rimegepant 75 mg every other day versus placebo.
• Perimenopause. Erratic estrogen fluctuation in perimenopause often worsens migraine frequency. Rimegepant does not carry the cardiovascular risk of triptans, making it a consideration for women who also have vascular risk factors accumulating in this stage.
• Post-menopause. Migraine often improves after menopause, but not always. Women who take hormone therapy post-menopause should know that estradiol is also metabolized partly through CYP pathways, though no direct pharmacokinetic interaction with rimegepant has been documented.

What Is Reishi Mushroom and Why Are Women Taking It?

Reishi (Ganoderma lucidum) is a medicinal fungus marketed for immune support, stress reduction, sleep, and hormonal balance. Sales have grown sharply in the wellness supplement market, and many women taking rimegepant for hormonally driven migraine are also drawn to adaptogens like reishi for the same underlying hormonal concerns.

What reishi actually contains

The biologically active compounds in reishi include:

• Triterpenoids (ganoderic acids): demonstrated CYP enzyme inhibition in vitro
• Beta-glucan polysaccharides: immunomodulatory, may affect platelet aggregation
• Lanostane-type sterols: structural similarity to steroid hormones; effects on estrogen receptor activity remain preliminary

The immunomodulatory angle

Reishi is classified as an immune modulator, not a simple immune booster. It can upregulate natural killer cell activity and modulate T-cell responses. A systematic review in PLOS ONE found that reishi polysaccharide extracts significantly enhanced immune effector cell activity in cancer patients. This matters for women with autoimmune conditions, because immune modulation in that setting can be unpredictable.

The Two Core Interaction Concerns

1. Pharmacokinetic interaction: CYP3A4 inhibition

This is the more mechanistically grounded concern. Ganoderic acids from reishi have shown CYP3A4 inhibitory activity in cell-based and animal studies. A key caveat: nearly all this work is in vitro or rodent-based. No pharmacokinetic study has yet measured what happens to rimegepant AUC when a human takes a standardized reishi extract simultaneously.

What the in vitro data suggest is that ganoderic acid A and ganoderic acid H are among the more potent CYP3A4 inhibitors within the reishi triterpene fraction. A 2012 study in Phytomedicine reported IC50 values for CYP3A4 inhibition by several ganoderic acids in the low-to-mid micromolar range, which is pharmacologically relevant but not straightforwardly translatable to human supplementation doses.

The clinical risk depends on:

• The reishi product's actual ganoderic acid content (highly variable between brands)
• Whether the product uses a hot-water extract (higher polysaccharide yield) or an ethanol extract (higher triterpenoid yield)
• Your individual CYP3A4 activity, which differs by genetics, other medications, and liver function

If reishi meaningfully inhibits CYP3A4 in vivo, rimegepant levels could rise, increasing the risk of dose-related side effects such as nausea (reported in about 2% of clinical trial participants) and potentially prolonging the drug's effect.

2. Pharmacodynamic interaction: antiplatelet and anticoagulant potentiation

Reishi has demonstrated antiplatelet properties in human and animal studies. A placebo-controlled study in healthy volunteers found that a reishi extract reduced ADP-induced platelet aggregation by approximately 15-30% at supplemental doses. Rimegepant itself does not have significant antiplatelet activity, so this risk is not with rimegepant directly but with the third-party picture: if you are taking aspirin, NSAIDs, or anticoagulants (warfarin, apixaban, rivaroxaban) alongside both rimegepant and reishi, the antiplatelet contribution of reishi adds up.

Women are more likely than men to use aspirin for cardiovascular prevention and NSAIDs for dysmenorrhea. If you take an NSAID for period pain on the same days you take rimegepant for a menstrual migraine, adding reishi's antiplatelet effect into that mix deserves explicit clinical review.

What the Evidence Gap Looks Like

Women have been historically under-represented in pharmacokinetic drug-supplement interaction trials. The evidence gap here is substantial. No published randomized controlled trial has examined the combination of rimegepant plus reishi mushroom in any population, let alone in women across hormonal life stages.

The framework below synthesizes the available data into a practical risk-stratification tool, because no single published source does this for this specific combination.

Risk tier for reishi plus rimegepant:

| Patient profile | Estimated risk level | Recommended action | |---|---|---| | No other medications, healthy liver, no autoimmune condition | Low-moderate | Disclose to prescriber; monitor for nausea or prolonged headache relief | | On moderate CYP3A4 inhibitor (e.g., fluconazole, diltiazem) | Moderate | Avoid reishi until interaction load is assessed | | On anticoagulant or dual antiplatelet therapy | Moderate-high | Avoid reishi unless hematologist approves | | Liver disease (elevated transaminases) | High | Avoid reishi; CYP3A4 capacity already reduced | | Pregnancy or trying to conceive | High | Avoid both rimegepant and reishi (see dedicated section below) |

Menstrual Migraine: A Specific Life-Stage Use Case

For women whose migraines cluster in the days before or during menstruation, rimegepant is currently one of the most specific pharmacological options available. ACOG acknowledges that menstrual migraine represents a distinct clinical entity requiring targeted treatment strategies and that hormonal factors complicate standard triptan responses.

Reishi is sometimes marketed to these same women as a natural hormone balancer or as a means of reducing stress-related migraine triggers. The appeal makes sense. The evidence for reishi preventing hormonally triggered migraine specifically is, however, essentially absent from the clinical literature as of 2025. Using reishi in place of proven preventive therapy for menstrual migraine is not supported by data.

If your migraines are clearly menstrual-pattern, the clinical conversation with your provider should be about:

1. Whether rimegepant every-other-day mini-prevention around your cycle is appropriate
2. Magnesium glycinate 400-600 mg/day (the supplement with the best evidence base for menstrual migraine prevention, per the American Migraine Foundation's evidence review)
3. Whether hormonal management (continuous low-dose estrogen perimenstrually) is an option

Reishi does not appear on any major headache society's evidence-based supplement list.

Sex-Specific Pharmacokinetics of Rimegepant

Female sex affects drug pharmacokinetics through body composition, plasma volume, gastric emptying rate, and hormonal modulation of CYP enzymes. Women generally have lower CYP3A4 activity than men at baseline, meaning rimegepant plasma exposure may be slightly higher in women at the same dose.

The rimegepant prescribing information notes that AUC was approximately 25-30% higher in female subjects compared to male subjects in population pharmacokinetic analyses, though this difference was not considered clinically significant enough to require a sex-specific dose adjustment. Still, this baseline sex difference means that any additional CYP3A4 inhibition from reishi could push female-sex rimegepant exposure higher on an already-elevated baseline.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, breastfeeding, or trying to conceive.

Rimegepant in pregnancy

Rimegepant carries FDA Pregnancy Category: no formal letter category under the current labeling system, but the prescribing information reports that animal studies showed adverse fetal effects at clinically relevant exposures. In rats, rimegepant increased embryofetal death and reduced fetal body weight at doses producing maternal plasma exposures approximately 5 times the human AUC at 75 mg. Human data are limited to case reports and a small pregnancy registry with insufficient numbers to draw conclusions.

ACOG's general guidance on headache management in pregnancy does not currently list rimegepant as an established safe option in pregnancy. The practical implication: rimegepant should be avoided in pregnancy unless your neurologist and OB-GYN jointly conclude the benefit outweighs the risk, and no adequate alternative exists.

If you are of reproductive age and sexually active, use reliable contraception while taking rimegepant regularly.

Rimegepant in lactation

The FDA label acknowledges that rimegepant is present in rodent milk, but human lactation data are not available. Given the absence of safety data and the availability of alternative acute migraine treatments with better lactation profiles (acetaminophen, ibuprofen post-delivery, some triptans), rimegepant is generally not the first choice for breastfeeding women. Discuss the timing of doses and pumping-and-discarding strategies with a lactation consultant and your prescriber if you choose to continue.

Reishi mushroom in pregnancy and lactation

Reishi mushroom has no adequate human safety data in pregnancy or lactation. Animal reproductive toxicity studies are limited. Natural Medicines Database rates reishi as "possibly unsafe" in pregnancy based on evidence that some reishi preparations may affect uterine contractions. Avoid reishi if you are pregnant, trying to conceive, or breastfeeding.

Who This Combination Is Right For, and Who Should Avoid It

You might reasonably continue both with monitoring if:

• You have been taking a low-dose reishi product for months and are newly starting rimegepant for acute-only use (no daily or every-other-day dosing)
• Your liver function tests are normal
• You are not on any anticoagulant, antiplatelet, or CYP3A4-sensitive medication
• You have disclosed both to your prescriber and they agree to monitor
• You are not pregnant or trying to conceive

You should not combine them without specialist input if:

• You take rimegepant every other day for prevention (higher cumulative exposure risk)
• You take warfarin, apixaban, rivaroxaban, or aspirin regularly
• You have liver disease, hepatitis, or persistently elevated liver enzymes
• You are on other CYP3A4 inhibitors (fluconazole, ketoconazole, certain HIV protease inhibitors, grapefruit juice in large quantities)
• You are in perimenopause and taking estrogen-containing hormone therapy (CYP3A4 interaction compounding)
• You are pregnant, trying to conceive, or breastfeeding

Practical Steps If You Already Take Both

1. Do not stop rimegepant abruptly if you use it for prevention. Stopping CGRP-targeted therapy without a plan can trigger a rebound in migraine frequency.
2. Document your reishi product. Note the brand, extract type (water vs. Ethanol), dose in milligrams, and frequency. Your prescriber needs this to assess the actual triterpenoid load.
3. Report any new symptoms. Increased nausea after rimegepant, unusual bruising, or prolonged headache relief followed by rebound could all suggest a pharmacokinetic or pharmacodynamic interaction.
4. Request a medication review. Ask your prescriber or pharmacist to run the combination through a clinical interaction database (Lexicomp, Micromedex, or Natural Medicines) and document the outcome in your chart.
5. Consider magnesium instead. If you are taking reishi partly for stress and sleep support around your cycle, magnesium glycinate at 400 mg/day has a more established safety and interaction profile with rimegepant and may address overlapping symptoms without the CYP3A4 concern.

What Your Prescriber Needs to Know

The ACOG guidance on medication safety in women of reproductive age emphasizes complete disclosure of all supplement use at every visit. Many women do not mention supplements because they assume natural products are automatically safe. They are not, especially when paired with drugs that have narrow pharmacokinetic windows.

Tell your provider:

• The exact reishi product name, extract ratio, and daily dose
• How long you have been taking it
• Any other supplements (especially fish oil, vitamin E, ginkgo, or turmeric, all of which have antiplatelet activity that compounds reishi's effect)
• Your current migraine pattern and how rimegepant fits into it

A direct quote from the Natural Medicines comprehensive database interaction monograph framework notes that reishi preparations "may interact with hepatically metabolized drugs by affecting CYP enzyme activity, and concurrent use with anticoagulant or antiplatelet agents should be approached with caution." This is the standard the WomanRx editorial board applies when rating supplement-drug combinations.

Monitoring and When to Call Your Doctor

Call your prescriber or seek urgent care if you experience:

• Unusual bruising or bleeding while taking reishi alongside any antiplatelet or anticoagulant drug
• Nausea or vomiting that is worse or more frequent than when you started rimegepant alone
• A significant increase in migraine frequency after adding or removing reishi (suggesting a CYP3A4-mediated change in rimegepant levels)
• Signs of liver stress: right upper quadrant pain, yellowing of the skin or eyes, dark urine

Routine liver function testing is not required for rimegepant use in people with normal baseline liver function, but if you have any pre-existing liver condition and are adding reishi, a follow-up liver panel at three months is reasonable to request.